Lung adenocarcinoma harboring rare epidermal growth factor receptor L858R and V834L mutations treated with icotinib: A case report.

Background: Epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitors are widely used for the treatment of non-small-cell lung cancer with mutations. However, patients with rare, even compound mutations have different responses to EGFR-tyrosine-kinase inhibitors, which bring uncertainty to clinical treatment.

Case Summary: A 45-year-old female patient presented with a 3-mo history of cough and white sputum without chest pain.